Novo Nordisk stock target increased, buy rating held on trial results
Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...
Healio9h
STEP UP: High-dose semaglutide led to 21% weight loss for adults with obesity
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...
Yahoo Finance4d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
When evaluating the effects of treatment if all people adhered to treatment 1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of ...
Semaglutide can also be beneficial to people with type 1 diabetes, clinical trial finds
Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...
Yahoo Finance4d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo. When evaluating the effects of ...
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
News Medical on MSN6d
Semaglutide improves glycemic control with automated insulin delivery
Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...
Mena FN4d
Novo Nordisk A/S: Semaglutide 7.2 Mg S.C. Achieved 20.7% Weight Loss In The STEP UP Obesity Trial, And 18.7% Regardless Of Treatment Adherence
STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide ... consistent with the GLP-1 receptor agonist class. “We are very pleased ...